Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 303
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | ||
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | ||
| NCT01737255 | Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome | ||
| NCT01941849 | Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | ||
| NCT05554523 | How Does Skin Tone Affect Quantitative Photoacoustic Imaging | ||
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | ||
| NCT02530411 | Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer | ||
| NCT00032175 | Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | ||
| NCT00509561 | Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer | ||
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | ||
| NCT00977210 | Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors | ||
| NCT02223923 | Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours | ||
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. | ||
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | ||
| NCT00532194 | An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer | ||
| NCT01140737 | A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas | ||
| NCT01926236 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers | ||
| NCT00005056 | Bryostatin 1 In Treating Patients With Progressive Kidney Cancer | ||
| NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | ||
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | ||
| NCT01862003 | Phase I/II Trial of Antagonism of HER in GI Cancer | ||
| NCT03994653 | Cancer Loyalty Card Study | ||
| NCT00112931 | Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | ||
| NCT03529669 | Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer | ||
| NCT03687645 | Hyperpolarised 13C-Pyruvate MRI Study | ||
| NCT03432429 | Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study | ||
| NCT01505829 | Diffusion-weighted Imaging Study in Cancer of the Ovary | ||
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations | ||
| NCT01585701 | Phase I Study of AT13148, a Novel AGC Kinase Inhibitor | ||
| NCT01551459 | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma | ||
| NCT06289374 | Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery | ||
| NCT07172958 | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) | ||
| NCT04271371 | Preventing Relapse to Smoking Among Prisoners After Release | ||
| NCT03328247 | Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma | ||
| NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer | ||
| NCT02121639 | Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy | ||
| NCT05537844 | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma | ||
| NCT00814567 | Radiation Therapy in Women With Low Risk Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery | ||
| NCT03934164 | Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO | ||
| NCT00755885 | Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer | ||
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | ||
| NCT01118611 | Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors | ||
| NCT02664935 | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | ||
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer | ||
| NCT00555386 | Soy, Selenium and Breast Cancer Risk | ||
| NCT01726374 | Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours | ||
| NCT03004755 | The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study | ||
| NCT00134108 | Clinical Benefit of Cognitive Behaviour Therapy (CBT) for Insomnia in Cancer Patients | ||
| NCT01331525 | The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer | ||
| NCT02741856 | Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation |
